Advanced Enzyme Technologies Limited – Investor Presentation Summary

Key Operational Highlights

  • Revenue from operations reached ₹1,898 million in Q1 FY27, representing 2% YoY growth but 7% QoQ decline
  • Human nutrition segment contributed 60% of total revenue but declined 7% YoY to ₹1,139 million
  • Animal nutrition segment contributed 13% of revenue, declining 3% YoY to ₹252 million
  • Industrial bio-processing segment grew 30% YoY to ₹306 million (16% of revenue)
  • Specialized manufacturing segment grew 41% YoY to ₹200 million (11% of revenue)

Segment-wise Performance

  • Human Nutrition: ₹1,139 million (60% of total), declined 7% YoY and 11% QoQ
  • Animal Nutrition: ₹252 million (13% of total), declined 3% YoY but grew 1% QoQ
  • Industrial Bio-processing: ₹306 million (16% of total), grew 30% YoY but declined 5% QoQ
  • Food business within industrial segment grew 51% YoY to ₹263 million
  • Non-food business declined 30% YoY to ₹43 million
  • Specialized Manufacturing: ₹200 million (11% of total), grew 41% YoY and 11% QoQ

Financial Highlights

  • Revenue: ₹1,898 million in Q1 FY27
  • EBITDA: ₹510 million, declined 10% YoY and 19% QoQ
  • PAT: ₹386 million, declined 5% YoY and 15% QoQ
  • EPS: ₹3.31, declined 7% YoY and 14% QoQ
  • Margins: EBITDA margin 27%, PAT margin 20%
  • YoY comparison: Revenue +2%, EBITDA -10%, PAT -5%
  • QoQ comparison: Revenue -7%, EBITDA -19%, PAT -15%
  • Drivers of financial performance: Mixed segment performance with industrial bio-processing and specialized manufacturing growth offset by human nutrition decline

Geographical Revenue Split

  • India: 46% of FY26 revenue
  • Americas: 37% of FY26 revenue
  • Europe: 5% of FY26 revenue
  • Asia (ex-India): 9% of FY26 revenue
  • Rest of the World: 3% of FY26 revenue

Balance Sheet Snapshot

  • Net Debt: ₹(1,558) million (negative net debt position)
  • Reserves: Part of Other Equity at ₹16,096 million (Mar 2026)
  • Current Assets: ₹10,436 million (Mar 2026)
  • Current Liabilities: ₹1,067 million (Mar 2026)
  • Financial Health Insights: Strong cash position with negative net debt, comfortable liquidity position

Capex & Cash Flow Health

  • Capital Expenditure: Not specified for current period
  • Net Working Capital Days: 97 days (FY26)
  • Investment Rationale: Focus on R&D and geographical expansion

Strategic & R&D Initiatives

  • Investments in Innovation: Continued investment in enzyme and probiotic development, genetic engineering capabilities
  • Strategic Rationale: Replace traditionally used chemicals with eco-friendly enzymatic solutions across various industries
  • Company has developed 400+ products serving 700+ customers worldwide with 68+ enzymes developed since 1994

Industry Trends & Business Environment

  • Global enzyme market opportunity identified across multiple segments
  • Human Nutrition addressable market: $560 million over next 5 years
  • Animal Nutrition addressable market: $800 million over next 5 years
  • Bio-Processing addressable market: $485 million over next 5 years

Management Commentary & Growth Outlook

  • Focus areas: Animal nutrition trials and studies, bio-catalysis for API manufacturers, probiotics expansion, baking solutions
  • Geographical expansion plans: Strengthening presence in USA, MENA and Asian markets
  • Growth targets: Targeting specific addressable market opportunities with CAGRs of 6-14% across segments
  • Company aims to become largest enzyme and probiotic-based value provider globally

ESG Updates

Not Specified

Digital Transformation

Not Specified